Laquinimod reduces neuroaxonal injury through inhibiting microglial activation

OBJECTIVE: Laquinimod is an emerging oral medication for multiple sclerosis (MS) that reduces brain atrophy and progression of disability in two Phase III clinical trials. The mechanism of these effects is unclear. Persistent activation of microglia occurs in MS and contributes to injury. Thus, we i...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Mishra, Manoj Kumar, Wang, Janet, Keough, Michael B, Fan, Yan, Silva, Claudia, Sloka, Scott, Hayardeny, Liat, Brück, Wolfgang, Yong, V Wee
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Publishing Ltd 2014
Konular:
Research Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184669/
https://ncbi.nlm.nih.gov/pubmed/25356411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.67
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller